Pharma Synth Formulations Limited, a active public limited company, was established on 26 November 1993 in Delhi, Delhi, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U74899DL1993PLC056231. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹5.00 M and a paid-up capital of ₹5.00 M.
It upholds a compliant status. Employing 223 professional, Its leadership includes Phoolwati Jain (Director), Ramesh Chand Jain (Director), Arvind Kumar Gupta (Director). It holds ₹18.00 Cr open charges and ₹24.03 Cr settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at A - 10/15Jhilmil Industrial Area, Delhi, Delhi, 110095.
U74899DL1993PLC056231
056231
26 November 1993
₹5.00 M
₹5.00 M
Roc Delhi
Unlisted
Active
Explore comprehensive insights into Pharma Synth Formulations Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Phoolwati Jain | Director | 08 Mar 1994 | Current |
| Ramesh Chand Jain | Director | 26 Nov 1993 | Current |
| Arvind Kumar Gupta | Director | 26 Nov 1993 | Current |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Pharma Synth Formulations Limited, for the financial year ended 2024, experienced modest growth in revenue, with a 0.75% increase. The company also saw a substantial improvement in profitability, with a 25.43% increase in profit. The company's net worth Soared by an impressive increase of 11.97%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2024, Pharma Synth Formulations had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹180,000,000.00
₹240,322,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Sep 2024 | Sidbi | ₹8.00 Cr | Open |
| 13 Sep 2024 | Sidbi | ₹8.00 Cr | Open |
| 13 Sep 2024 | Sidbi | ₹2.00 Cr | Open |
| 20 Jan 2023 | Sidbi | ₹16.00 Cr | Satisfied |
| 28 Mar 2022 | Sidbi | ₹2.00 Cr | Satisfied |
Explore comprehensive loan charge details -
Pharma Synth Formulations has a workforce of 223 employees as of Mar 11, 2025. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Pharma Synth Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pharma Synth Formulations's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Pharma Synth Formulations Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was documented.
A charge registered on 20 Jan 2023 via Charge ID 100674524 with Sidbi was fully satisfied on 24 Sep 2024. was recorded as a recent event.
A charge registered on 28 Mar 2022 via Charge ID 100551116 with Sidbi was fully satisfied on 24 Sep 2024. was recorded as a recent event.
The activity A charge with Sidbi amounted to Rs. 80.00 M with Charge ID 100979051 was registered on 13 Sep 2024. was completed.
Progress on A charge with Sidbi amounted to Rs. 80.00 M with Charge ID 100979003 was registered on 13 Sep 2024. was documented.
The activity A charge with Sidbi amounted to Rs. 20.00 M with Charge ID 100978996 was registered on 13 Sep 2024. was completed.
The CIN of Pharma Synth Formulations Limited is U74899DL1993PLC056231.
Pharma Synth Formulations Limited is headquartered at A - 10/15Jhilmil Industrial Area, Delhi, Delhi, 110095.
Pharma Synth Formulations Limited was incorporated on 26 November 1993.
The current directors of Pharma Synth Formulations Limited are
The primary industry of Pharma Synth Formulations Limited is Manufacturing.
Pharma Synth Formulations Limited is unlisted.
The authorized capital of Pharma Synth Formulations Limited is ₹5.00 M, and the paid-up capital is ₹5.00 M.
The compliance status of Pharma Synth Formulations Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX